Tuesday, November 19, 2019
News
NEWS HOME
»
PRESS RELEASES

Takeda Acquires License for First-In-Class Celiac Disease Therapy from COUR Pharmaceuticals Following Positive Phase 2a Proof-of-Concept Study
  SocialTwist Tell-a-Friend  
   


Date: 23-10-2019 10:30AM
Source: Takeda Pharmaceutical Company Limited
Category: General, Science & Research, Healthcare & Biotechnology, Pharmaceutical
Location: Osaka, Japan & CHICAGO, United States

Business Wire India

− Late-breaking data presented from a Phase 2a trial at UEG Week 2019, Barcelona, Spain, highlights potential of investigational medicine to prevent gluten induced immune activation in patients with celiac disease
− Takeda acquires exclusive global license to investigational medicine CNP-101/TAK-101, an immune modifying nanoparticle designed to induce tolerance to gluten in patients with celiac disease


Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) and COUR Pharmaceutical Development Company, Inc. (“COUR”) announced that Takeda has acquired an exclusive global license to develop and commercialize the investigational medicine CNP-101/TAK-101, an immune modifying nanoparticle containing gliadin proteins. Based on COUR’s antigen specific immune tolerance platform, TAK-101 is a potential first-in-class treatment targeting the aberrant immune response in celiac disease, a serious autoimmune disease where the ingestion of gluten leads to inflammation and damage in the small intestine.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191021005739/en/

Results of a randomized, double-blind, placebo-controlled clinical trial to assess the markers of potential efficacy and safety of the investigational medicine in 34 adults with proven celiac disease was presented today as a late-breaking abstract at UEG Week 2019, Barcelona, Spain. At inclusion, patients had well-controlled biopsy proven celiac disease. After inclusion, they underwent an oral gluten challenge. Based on the study, Takeda exercised its option to acquire the exclusive global license to TAK-101.

“While many people living with celiac disease can manage their symptoms by following a gluten free diet, there are currently no treatment options for those who continue to have symptoms,” said Asit Parikh M.D., Ph.D., Head, Gastroenterology Therapeutic Area Unit at Takeda. “Our collaboration with COUR has shown, for the first time, that it is possible to induce specific immune tolerance to a foreign antigen in autoimmune diseases such as celiac disease. With our expertise in inflammatory diseases, Takeda is well positioned to further develop TAK-101 in pursuit of providing the first approved treatment option for patients with celiac disease.”

In the trial, treatments were administered intravenously on day 1 and day 8. The gluten challenge began seven days after the second treatment administration and included 12 grams of gluten per day for three days followed by 6 grams of gluten per day for 11 days. The primary endpoint was change from baseline in interferon-gamma (IFN-γ) spot forming units (SFUs) at day 6 after gluten challenge using a gliadin-specific enzyme-linked immunospot (ELISpot) assay. This test is a direct measure of gluten-specific systemic T cell activation in celiac disease, and blocking this response suggests individuals with celiac disease could be protected from the effects of gluten exposure. 34 patients were randomized and treated, 6 discontinued due to gluten related symptoms, and 28 completed the 14-day gluten challenge per protocol.

The primary endpoint of the trial was achieved with a mean change from baseline in IFN-γ ELISpotSFUs of 2.10 and 17.57 with TAK-101 and placebo, respectively (p=0.0056). Also seen was a trend in protection from small intestinal mucosal damage with deterioration of 0.18 with TAK-101 compared with 0.63 with placebo (p=0.079). The most frequent adverse events in patients receiving TAK-101 that exceeded the frequency seen in placebo treated patients were nausea, headache, abdominal pain, and back pain. No patient had clinically significant changes in vital signs, routine clinical labs, or serum cytokines/chemokines, gliadin-specific T cell proliferation and cytokine secretion.

Takeda intends to initiate a dose-ranging study to further explore the potential of TAK-101 in the treatment of patients with celiac disease on a gluten free diet to inform future registrational trials. COUR is eligible to receive up to $420 million in future payments, and royalties on sales of any commercialized products resulting from the license.

“We are encouraged by the data from this first human proof of concept study of our proprietary nanoparticle platform designed to reprogram the immune system,” said John J. Puisis, CEO of COUR Pharmaceuticals. “As Takeda assumes responsibility for the celiac disease program, COUR will focus on advancing our pipeline of therapies for a variety of other immune disorders ranging from multiple sclerosis to peanut allergy.”

COUR’s proprietary immune modifying nanoparticles bind inflammatory cells to initiate tolerogenic immune reprogramming. The interior core can be loaded with disease specific antigen – in this case, gliadin proteins – to induce tolerance in autoimmune conditions like celiac disease.

About Celiac Disease
Celiac disease is a genetically driven chronic immune-mediated disorder where abnormal immune responses to gluten peptides lead to small intestinal mucosal damage.1,2,3 Recent population-based studies in the U.S. indicate that the prevalence of celiac disease is around 1%4 and approximately 0.5% globally.5 The threshold of daily gluten that will cause mucosal injury in both adults and children is 10 to 50mg per day – or about 1/100th of a slice of bread.6,7 Celiac disease can cause symptoms including abdominal pain, diarrhea, nausea, and vomiting. Long-term complications of celiac disease may include malnutrition, accelerated osteoporosis, nervous system problems and problems related to reproduction. Currently the only available treatment for patients with celiac disease is maintaining a gluten-free diet, which involves strict, lifelong avoidance of exposure to gluten proteins from wheat, barley, and rye, which is not always effective.8

Takeda’s Commitment to Gastroenterology
Gastrointestinal (GI) diseases can be complex, debilitating, and life-changing. Recognizing this unmet need, Takeda and our collaboration partners have focused on improving the lives of patients through the delivery of innovative medicines and dedicated patient disease support programs for over 25 years. Takeda aspires to advance how patients manage their disease. Additionally, Takeda is leading in areas of gastroenterology associated with high unmet need, such as inflammatory bowel disease, acid-related diseases, and motility disorders. Our GI Research & Development team is also exploring solutions in celiac disease and liver diseases, as well as scientific advancements through microbiome therapies.

About COUR Pharmaceuticals
COUR Pharmaceuticals is developing first-in-class therapies designed to reprogram the immune system to achieve antigen-specific tolerance for immune-mediated disease. COUR’s platform of immune-modifying nanoparticles treats the root cause of immune disease unlike traditional approaches, which only minimize symptoms using toxic immune suppression. COUR’s lead product for celiac disease, partnered with Takeda, is the first demonstration of induction of antigen-specific immune tolerance in any autoimmune disease. Data from clinical and preclinical settings demonstrate the opportunity for the COUR nanoparticle platform to address a wide range of immune and inflammatory conditions. The underlying technology was acquired from Northwestern University and draws from more than 30 years of research by the laboratory of Stephen D. Miller, Ph.D., the Judy E. Guggenheim Research Professor of Microbiology-Immunology. For more information, visit www.courpharma.com.

About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Rare Diseases and Neuroscience. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.

For more information, visit https://www.takeda.com

Forward-Looking Statements
This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. Forward-looking statements in this document are based on Takeda’s estimates and assumptions only as of the date hereof. Such forward-looking statements do not represent any guarantee by Takeda or its management of future performance and involve known and unknown risks, uncertainties and other factors, including but not limited to: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations; the success of or failure of product development programs; decisions of regulatory authorities and the timing thereof; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the timing and impact of post-merger integration efforts with acquired companies; and the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s), any of which may cause Takeda’s actual results, performance, achievements or financial position to be materially different from any future results, performance, achievements or financial position expressed or implied by such forward-looking statements. For more information on these and other factors which may affect Takeda’s results, performance, achievements, or financial position, see “Item 3. Key Information—D. Risk Factors” in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/reports/sec-filings/ or at www.sec.gov. Future results, performance, achievements or financial position of Takeda could differ materially from those expressed in or implied by the forward-looking statements. Persons receiving this press release should not rely unduly on any forward-looking statements. Takeda undertakes no obligation to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results of Takeda in this press release may not be indicative of, and are not an estimate, forecast or projection of Takeda’s future results.

1 Jabri B, Sollid LM. T Cells in Celiac Disease. J Immunol 2017;198:3005-3014.
2 Molberg O, McAdam S, Lundin KE, et al. T cells from celiac disease lesions recognize gliadin epitopes deamidated in situ by endogenous tissue transglutaminase. Eur J Immunol 2001;31:1317-23.
3 Dieterich W, Ehnis T, Bauer M, et al. Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat Med 1997;3:797-801.
4 Leonard MM, Sapone A, Catassi C, et al. Celiac Disease and Nonceliac Gluten Sensitivity: A Review. JAMA 2017;318:647-656.
5 Lionetti E, Gatti S, Pulvirenti A, et al. Celiac disease from a global perspective. Best Pract Res Clin Gastroenterol 2015;29:365-79.
6 Might gluten traces in wheat substitutes pose a risk in patients with celiac disease? A population-based probabilistic approach to risk estimation. Am J Clin Nutr 2013;97:109-16.
7 Catassi C, Fabiani E, Iacono G, et al. A prospective, double-blind, placebo-controlled trial to establish a safe gluten threshold for patients with celiac disease. Am J Clin Nutr 2007;85:160-6.
8https://www.niddk.nih.gov/health-information/digestive-diseases/celiac-disease/symptoms-causes (accessed October 9, 2019)



CONTACTS :

Takeda Pharmaceuticals
Media in Japan
Kazumi Kobayashi
+81 (0) 3-3278-2095
kazumi.kobayashi@takeda.com

U.S Media
Chris Stamm
+1 (617) 374-7726
chris.stamm@takeda.com

European Media
Luke Willats
+41 44-555-1145
luke.willats@takeda.com

COUR Pharmaceuticals
Canale Communications
Mari Purpura
+1 (619) 849-5384
mari@canalecomm.com

More Press Releases

Harness the Power of the Bajaj Finserv Business Loan for Doctors

RP tech India Brings Plantronics True Wireless Earbuds BackBeat PRO 5100 to the Market

GoDaddy Brings Ease to Customers With WooCommerce Integration and Updates to GoDaddy WordPress Hosting

Mori Memorial Foundation’s GPCI 2019 Report: London Loses Momentum, Tokyo Is Sluggish and Paris Trends Upward

Diagnose COPD Early to Prevent Lung Attack

GIA India Donates Replicas of Famous Diamonds to Chhatrapati Shivaji Maharaja Vastu Sangrahalaya

Northern Bitcoin Merges With Leading US Competitor

Lineage Logistics Announces Acquisition of Emergent Cold, Expands U.S. Port Network and Strategic Presence in Asia-Pacific Market

New Graduates Highlight Petrofac’s Long-term Commitment to India

China Hi-Tech Fair 2019 (CHTF2019) Concludes in Shenzhen

MSCI Launches Private Offering of $250 Million Senior Notes Due 2029

MSCI Prices $500 Million 4.000% Senior Notes Due 2029

OPPO’s All-New ColorOS 7 to Launch in India on 26th November

JICA Supports Biodiversity Conservation and Human-Wildlife Conflict Resolution Workshop in Sikkim

The Estée Lauder Companies to Acquire Dr. Jart+

Kantar and VTION™ Announce Partnership to Roll out India’s First Continuous ‘OTT Audience Measurement’ Solution

NewQuest Raises US$1 Billion For Its Fourth Flagship Fund

IDEMIA Launches the Very First Metal Card in Belgium, With Nagelmackers Bank

Cooper Tire Europe Launches Extensive New Rally Tire Range for Tarmac, Classic Tarmac, Gravel and Mud and Snow Applications

Mumbai to Host Asia’s Largest Show on Smart and Safe Mobility on November 20

The Estée Lauder Companies Becomes First Prestige Beauty Company to Execute a Virtual Power Purchase Agreement for Renewable Energy

QIAGEN Receives Several Conditional, Non-binding Indications of Interest, and Decides to Enter Into Discussions to Explore Potential Strategic Alternatives

Interim analysis from EMPRISE real-world study shows empagliflozin decreased risk of hospitalisation for heart failure compared with DPP-4 inhibitors and GLP-1 receptor agonists

Dubai Future Accelerators to Pick New Cohort of Innovative Startups to Address Global Challenges

Certain Units in Oosten Condominium Brooklyn, New York to be Tokenized Through UPRETS

Pengmen International Trading Company Developed a Series of Health Products by Using the Medicinal Value of Red Sandalwood

DaraPay Announces Strategic Partnership with Chinese Tech Giant- Alipay

At CIIE 2019 Panasonic Showcases Solutions to Help Bring to Life China's "Healthy China 2030" Vision

Taro Announces Commencement of Tender Offer to Repurchase up to $225 Million in Value of Its Ordinary Shares

Messe Frankfurt India to Host India’s First Technical Textile Hackathon at Techtextil India 2019

Velodyne Lidar Debuts Alpha Prime™, the Most Advanced Lidar Sensor on the Market

Korean Cultural Festival 2019 Held in Mumbai During 15th and 16th November 2019

Ghosts of Bill Stir People in Dineout’s Extension of FearNoBill Campaign

Airtel, Milton and Royal Enfield Win at the 2019 World Branding Awards at Kensington Palace

Corporate Social Responsibility Related News Releases and Story Ideas for Reporters, Bloggers and Media Outlets

The Many Benefits of Investing in Bajaj Finance Senior Citizen Fixed Deposit Scheme

Alibaba Group Launches Hong Kong Initial Public Offering

Heilind Asia Awarded the “Top 10 International Branded Distributors” From ASPENCORE

The International Board of Lactation Consultant Examiners (IBLCE) selects Prometric for Global Examination Administration

Nahyan bin Mubarak Inaugurates World Tolerance Summit in Dubai

ABI Research Names PTC a Leader in Enterprise Augmented Reality Platforms

KIOXIA Corporation Introduces Industry’s First[1] 512GB Automotive UFS

Century Real Estate Unveils Century Horizon at Business Associate Meet

Alipay Aims to Help 10 Million European Merchants Reach Over 2 Billion Potential Consumers in Five Years With Innovative Technology

Esri Joins Autodesk University 2019 Conference

Vista Equity Partners Announces Asia Expansion

Takeda Announces 12 New Molecular Entities with the Potential for 14 Launches in the Next Five Years at 2019 R&D Day

 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
INDIA WORLD ASIA
PM Modi pays tributes to Indira Gandhi o...
Student leader arrested for assaulting c...
Agitating JNU students return to campus ...
JNU student protest taking partisan hue...
CPI's Binoy Viswan gives suspension of b...
Air quality improves slightly in Delhi, ...
More...    
 
 Top Stories
'Libyan conflict inflicts devastati... 
K'taka: Cong MLA Tanveer Sait's gun... 
Maharashtra: 2 killed, 17 injured i... 
Ben Laughlin signs two year deal wi... 
Auto registrations rose by 4 pc in ... 
PM Modi condoles demise of UAE Pres... 
RP tech India brings Plantronics Tr... 
Airfares to Australia that will bow...